# US 2023/0263818 A1 · Combination decitabine and cedazuridine solid oral dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0263818 A1
- Document ID: US20230263818A1
- Status: Published application
- Kind: A1
- Application number: 18/309,440
- Filed: 2023-04-28
- Published: 2023-08-24
- Earliest claimed: 2020-02-25
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Applicants: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Aram Oganesian; Nipun Davar; Jim Hwaicher Kou
- Web page: https://patentgrep.com/patent/US20230263818A1

## CPC

- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/717: Celluloses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.

## Claims

### Claim 1

A solid oral dosage form comprising cedazuridine and decitabine, wherein the solid oral dosage form upon daily administration to a human provides plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily intravenous dose of decitabine of 20 mg/m2 administered as a 1 h infusion.

### Claim 2 (depends on 1)

The solid oral dosage form of claim 1, wherein upon daily administration to a human the ratio of AUC for decitabine on day 2 versus day 1 is about 1.5:1 to about 2:1.

### Claim 3 (depends on 1)

The solid oral dosage form of claim 1, wherein the solid oral dosage form upon daily administration to a human provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a 1 h infusion.

### Claim 4 (depends on 3)

The solid oral dosage form of claim 3, wherein the pharmacodynamic effect is DNA demethylation.

### Claim 5 (depends on 1)

The solid oral dosage form of claim 1, which is a tablet.

### Claim 6 (depends on 1)

The solid oral dosage form of claim 1, which is a capsule.

### Claim 7 (depends on 1)

The solid oral dosage form of claim 1, comprising decitabine and cedazuridine in a weight ratio of about 30:100 to about 40:100.

### Claim 8 (depends on 7)

The solid oral dosage form of claim 7, comprising decitabine and cedazuridine in a weight ratio of about 35:100.

### Claim 9 (depends on 1)

The solid oral dosage form of claim 1, comprising about 100 mg cedazuridine.

### Claim 10 (depends on 1)

The solid oral dosage form of claim 1, comprising about 35 mg decitabine.

### Claim 11 (depends on 1)

The solid oral dosage form of claim 1, further comprising one or more of a diluent, binder, disintegrant, glidant, or lubricant.

### Claim 12 (depends on 1)

The solid oral dosage form of claim 1, further comprising a diluent, binder, disintegrant, glidant, and lubricant.

### Claim 13 (depends on 11)

The solid oral dosage form of claim 11, wherein the diluent comprises at least one of lactose, lactose monohydrate, cellulose, sorbitol, dibasic calcium phosphate dehydrate, and calcium sulfate dehydrate.

### Claim 14 (depends on 11)

The solid oral dosage form of claim 11, wherein the binder comprises at least one of gelatin, glucose, lactose, cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, starch, poly vinyl pyrrolidone, sodium alginate, carboxymethylcellulose, and acacia.

### Claim 15 (depends on 11)

The solid oral dosage form of claim 11, wherein the disintegrant comprises at least one of croscarmellose sodium, crospovidone, sodium starch glycollate, and starch.

### Claim 16 (depends on 11)

The solid oral dosage form of claim 11, wherein the glidant comprises at least one of colloidal silicon dioxide, cornstarch, and talc.

### Claim 17 (depends on 11)

The solid oral dosage form of claim 11, wherein the lubricant comprises at least one of stearic acid, magnesium stearate, calcium stearate, talc, paraffin, sodium lauryl sulphate, sodium benzoate, and polyethylene glycol.

### Claim 18 (depends on 11)

The solid oral dosage form of claim 11, further comprising lactose monohydrate, hydroxypropyl methylcellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.

### Claim 19 (depends on 1)

The solid oral dosage form of claim 1, further comprising a coating.

### Claim 20 (depends on 19)

The solid oral dosage form of claim 19, wherein the coating is a color coating.

### Claim at position 21

-38. (canceled)
